NervGen Pharma Q1 2026 Earnings Report

NervGen Pharma EPS Results

• Actual EPS: $999.00
• Consensus EPS: -$0.07
• Beat/Miss: Beat by +$999.07
• One Year Ago EPS: N/A

NervGen Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NervGen Pharma Announcement Details

• Quarter: Q1 2026
• Date: 5/15/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

NervGen Pharma (NASDAQ:NGEN) Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings. NervGen’s development activities center on progressing NVG-291 and related research through clinical trials to assess safety, tolerability and potential to improve functional outcomes for patients with neurological damage.

NervGen is publicly traded on the NASDAQ under the ticker NGEN and operates as a research-driven biopharmaceutical organization. The company conducts clinical development activities and research collaborations to support its programs and to advance regulatory development pathways for its therapeutics.

As a clinical-stage company, NervGen’s prospects are tied to the progress and results of its clinical trials and development partnerships. Its work is representative of the broader effort in biotechnology to develop novel regenerative treatments for conditions with significant unmet medical need in neurology. Investors and stakeholders typically follow clinical milestones and regulatory updates when evaluating the company’s progress.